IQV:NYE- (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 176.3

Change

-1.09 (-0.61)%

Market Cap

USD 33.79B

Volume

2.23M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-31 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 151.57B
A Agilent Technologies Inc

N/A

USD 36.12B
LH Laboratory Corporation of Amer..

N/A

USD 21.18B
DGX Quest Diagnostics Incorporated

N/A

USD 18.88B
CRL Charles River Laboratories

N/A

USD 9.00B
QGEN Qiagen NV

N/A

USD 8.30B
ENZ Enzo Biochem Inc

N/A

USD 0.03B
TMO Thermo Fisher Scientific Inc

N/A

N/A
WAT Waters Corporation

N/A

N/A
MTD Mettler-Toledo International I..

N/A

N/A

ETFs Containing IQV

EKG First Trust Nasdaq Lux Di.. 6.09 % 0.00 %

N/A

USD 2.40M
BBH VanEck Biotech ETF 4.25 % 0.35 %

N/A

USD 0.40B
IBB iShares Biotechnology ETF 3.33 % 0.47 %

N/A

USD 6.00B
GNRX 0.00 % 0.55 %

N/A

N/A
PBI Pitney Bowes Inc 0.00 % 0.79 %

N/A

USD 1.74B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
XSD2:LSE db x-trackers ShortDAX x2.. 0.00 % 0.00 %

N/A

USD 0.10B
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 0.00 % 0.00 %

N/A

USD 0.13B
VNMC 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.28% 54% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.28% 46% F 19% F
Trailing 12 Months  
Capital Gain -29.16% 25% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.16% 25% F 10% F
Trailing 5 Years  
Capital Gain 76.23% 45% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.23% 45% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 11.09% 75% C 69% C-
Dividend Return 11.09% 67% D+ 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.83% 42% F 35% F
Risk Adjusted Return 38.45% 67% D+ 53% F
Market Capitalization 33.79B 78% C+ 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.